News

The partnership will allow Cheminnova to gain significant stake in exchange for the intellectual property rights for RNL’s product range for some markets and the manufacturing rights for

Acceliant, a comprehensive clinical data management platform, will support Phase I-IV trials and post-marketing studies for all therapeutic areas and medical devices. The solution supports a clinical trial

Omkar Speciality manufactures speciality chemicals such as selenium compounds, iodine compounds, molybdenum compounds and pharma intermediates including potassium iodate, bismuth ammonium citrate, bromoform. The company has four units

According to the agreement, the company has agreed to issue an aggregate of 200,000 shares of its newly designated shares of Series C preferred stock in exchange for

The randomized double-masked placebo-controlled trial will recruit around 24 subjects with non-infectious, non-necrotizing anterior scleritis to assess the safety and tolerability of three ocular iontophoresis dose levels of

As per the agreement, Concert will receive an upfront payment and upon achievement of certain predefined clinical, regulatory and commercial targets, it is eligible to receive additional milestone

Opexa is developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS). Opexa president and chief executive officer Neil Warma said they are pleased with the depth of

Under the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments, and in return for its option to develop and commercialize products,

The company has gained an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The